Moderate and high amounts of tamoxifen in α-MHC-MerCreMer mice induce a DNA damage response, leading to heart failure and death
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Numerous mouse models have utilized Cre-loxP technology to modify gene expression. Adverse effects of Cre recombinase activity have been reported, including in the heart. However, the mechanisms associated with cardiac Cre toxicity are largely unknown. Here, we show that expression of Cre in cardiomyocytes induces a DNA damage response, resulting in cardiomyocyte apoptosis, cardiac fibrosis and cardiac dysfunction. In an effort to increase the recombination efficiency of a widely used tamoxifen-sensitive Cre transgene under control of the α-myosin-heavy-chain promoter (αMHC-MerCreMer), we observed myocardial dysfunction and decreased survival, which were dependent on the dose of tamoxifen injected. After excluding a Cre-independent contribution by tamoxifen, we found that Cre induced myocardial fibrosis, activation of pro-fibrotic genes and cardiomyocyte apoptosis. Examination of the molecular mechanisms showed activation of DNA damage response signaling and p53 stabilization in the absence of loxP sites, suggesting that Cre induced illegitimate DNA breaks. Cardiomyocyte apoptosis was also induced by expressing Cre using adenoviral transduction, indicating that the effect was not dependent on genomic integration of the transgene. Cre-mediated homologous recombination at loxP sites was dose-dependent and had a ceiling effect at ~80% of cardiomyocytes showing recombination. By titrating the amount of tamoxifen to maximize recombination while minimizing animal lethality, we determined that 30 μg tamoxifen/g body weight/day injected on three consecutive days is, in our lab, the optimal condition for the αMHC-MerCreMer system to induce recombination in the Rosa26-lacZ strain. Our results further highlight the importance of experimental design, including the use of appropriate genetic controls for Cre expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 2×
“Since submission of this paper, off-target activity of CRISPR/Cas9 in mammalian cells has been documented, highlighting the need for careful evaluation of unintended effects of expressing bacterial nucleases (Fu et al., 2013; Hsu et al., 2013; Pattanayak et al., 2013).”
BackgroundPattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487 · cited 2×
“Since submission of this paper, off-target activity of CRISPR/Cas9 in mammalian cells has been documented, highlighting the need for careful evaluation of unintended effects of expressing bacterial nucleases (Fu et al., 2013; Hsu et al., 2013; Pattanayak et al., 2013).”
BackgroundLi, J., Patel, V. V., Kostetskii, I., Xiong, Y., Chu, A. F., Jacobson, J. T., Yu, C., Morley, G. E., Molkentin, J. D., & Radice, G. L. (2005) · Circulation Research · doi:10.1161/01.res.0000181132.11393.18 · Cited by 223 · cited 1×
“To increase this recombination efficiency, we tested a range of tamoxifen doses, which we selected based on published protocols, namely 20 μg/g body weight (Sohal et al., 2001) and 80 μg/g body weight (Li et al., 2005).”
Method
Cited by
Hippo pathway deficiency reverses systolic heart failure after infarction
Leach, J. P., Heallen, T., Zhang, M., Rahmani, M., Morikawa, Y., Hill, M. C., Segura, A., Willerson, J. T., & Martin, J. F. (2017) · Nature · doi:10.1038/nature24045 · Cited by 422
Chen, Y.-C., Ma, N.-X., Pei, Z.-F., Wu, Z., Do-Monte, F. H., Keefe, S., Yellin, E., Chen, M. S., Yin, J.-C., Lee, G., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.003 · Cited by 312
YAP Partially Reprograms Chromatin Accessibility to Directly Induce Adult Cardiogenesis In Vivo
Monroe, T. O., Hill, M. C., Morikawa, Y., Leach, J. P., Heallen, T., Cao, S., Krijger, P. H. L., de Laat, W., Wehrens, X. H. T., Rodney, G. G., et al. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.01.017 · Cited by 289
“Telemetry electrocardiogram recordings similarly indicated that YAP5SA OE mice did not have severe arrhythmias, even when challenged with tam that causes T-wave inversion, as a consequence of transient Cre or tam toxicity in CMs 24 hours after tam (Bersell et al., 2013; Pugach et al., 2015) (Fig.”
BackgroundUsing the mouse to model human disease: increasing validity and reproducibility
Justice, M. J., & Dhillon, P. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.024547 · Cited by 281
“A companion paper provided evidence that tamoxifen itself can also have harmful effects on the organism (Bersell et al., 2013), which should also be considered when using a tamoxifen-inducible Cre driver.”
Polizzotti, B. D., Ganapathy, B., Walsh, S., Choudhury, S., Ammanamanchi, N., Bennett, D. G., dos Remedios, C. G., Haubner, B. J., Penninger, J. M., & Kühn, B. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5171 · Cited by 225
Self-citation
Metadata
- Authors
- Bersell, K., Choudhury, S., Mollova, M., Polizzotti, B. D., Ganapathy, B., Walsh, S., Wadugu, B., Arab, S., & Kühn, B.
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2013-01-01
- Volume
- 6
- Issue
- 6
- Pages
- 1459-69
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- OpenAlex
- W2099037109
- Cited by
- 143
- References
- 4
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.